We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 3,034 results

  1. Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome

    Low-dose prasugrel demonstrated a similar effectiveness profile to clopidogrel in East Asian ACS patients, but its comparison with another...

    Yee-Jen Wu, Chien-Chih Wu, ... Chi-Chuan Wang in Journal of Thrombosis and Thrombolysis
    Article 31 March 2024

  2. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel

    Background

    The ISAR-REACT 5 trial compared the efficacy and safety of ticagrelor and prasugrel in patients with ACS managed invasively. The present...

    Alp Aytekin, Maria Scalamogna, ... Salvatore Cassese in Clinical Research in Cardiology
    Article Open access 13 May 2024

  3. Usefulness of the PRECISE-DAPT score at differentiating between ticagrelor and prasugrel for dual antiplatelet therapy initiation

    As a part of dual antiplatelet therapy (DAPT), prasugrel or ticagrelor is prescribed along with aspirin to patients of acute coronary syndrome (ACS)...

    Avik Ray, Ahmad Najmi, ... Balakrishnan Sadasivam in Journal of Thrombosis and Thrombolysis
    Article 04 July 2023

  4. Efficacy and Safety of Dual Antiplatelet Therapy with the Routine Use of Prasugrel for Flow Diversion of Cerebral Unruptured Aneurysms

    Purpose

    Prasugrel is not approved for patients treated with flow diverters, which have a high metal coverage ratio. However, robust antiplatelet...

    Kenichiro Suyama, Ichiro Nakahara, ... Sadayoshi Watanabe in Clinical Neuroradiology
    Article Open access 17 October 2023

  5. Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor

    Background: Thrombin generation (TG), platelet function and circulating endothelial progenitor cells (EPCs) have an important role in the...

    Maya Wiessman, Mark Kheifets, ... Leor Perl in Journal of Thrombosis and Thrombolysis
    Article 04 January 2023

  6. Impact of Low-Dose Prasugrel on Platelet Reactivity in Chronic Phase of Post-Percutaneous Coronary Intervention (CHAPERON): a Prospective Cohort Study

    Purpose

    Asians often face the problems of clopidogrel resistance and East Asian paradox. This study aimed to evaluate the effects of P2Y 12 ...

    Tatsuya Fukase, Shinichiro Doi, ... Katsumi Miyauchi in Cardiovascular Drugs and Therapy
    Article 25 April 2023

  7. Comparison of Clopidogrel, Prasugrel and Ticagrelor Response of Patients by PFA-100-Innovance Test Results

    Devices such as stents and flow diverters require the use of safe and fast antiplatelet therapy. We aimed to compare the responses to clopidogrel,...

    Abdullah Sukun, Feyza Tekeli in Indian Journal of Hematology and Blood Transfusion
    Article 05 November 2022

  8. Prasugrel

    in Reactions Weekly
    Article 15 July 2023

  9. Prasugrel

    in Reactions Weekly
    Article 04 March 2023

  11. Prasugrel

    in Reactions Weekly
    Article 28 January 2023

  12. Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 map** study

    Purpose: Acute myocardial ischaemia triggers a non-specific inflammatory response of remote myocardium through the increase of plasma concentrations...

    Lara S. F. Konijnenberg, Daša Zugwitz, ... Robin Nijveldt in The International Journal of Cardiovascular Imaging
    Article 09 December 2022

  13. Real-world evidence of switching P2Y12 receptor–inhibiting therapies to prasugrel after PCI in patients with ACS: results from EFF-K registry

    Background

    Potent P2Y 12 inhibitors are recommended for up to 12 months after percutaneous coronary intervention (PCI) in patients diagnosed with...

    Jeehoon Kang, Jung-Kyu Han, ... Hyo-Soo Kim in BMC Cardiovascular Disorders
    Article Open access 09 January 2023

  14. Aspirin/prasugrel

    in Reactions Weekly
    Article 14 January 2023

  16. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease

    Switching P2Y 12 inhibitors is common in clinical practice. However, data on the pharmacodynamic (PD) effects of switching in clinical settings...

    Mattia Galli, Fabiana Rollini, ... Francesco Franchi in Journal of Thrombosis and Thrombolysis
    Article 01 September 2022

  18. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial

    Objectives

    To assess the efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndrome (ACS) presenting during off- and...

    Michael Behnes, Shqipdona Lahu, ... Ibrahim Akin in Clinical Research in Cardiology
    Article Open access 05 July 2022

  19. Prasugrel

    in Reactions Weekly
    Article 09 July 2022
Did you find what you were looking for? Share feedback.